Neurovalens earns FDA nod for neuromod for PTSD

Neurovalens announced today that it received FDA de novo approval for Modius Spero, a post-traumatic stress disorder (PTSD) therapy.

Belfast, Northern Ireland-based Neurovalens designed its Modius technology to use low-level electrical signals to non-invasively stimulate areas of the brain known to regulate key functions. This method is known as electrical vestibular system stimulation (VSS).

Modius Spero specifically targets the symptoms of PTSD. It stimulates deep parts of the brain, using small, safe electrical pulses delivered to the skin behind the ear. The treatment period lasts 30 minutes daily, while patients can perform other activities, like watching TV or reading, during therapy.

Sign up for Blog Updates